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Background: The purpose of this study was to investigate whether the excision repair cross-complementation
group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical
squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiotherapy (CCCRT).
Methods: A total of sixty LACSCC patients, treated with radical CCCRT from a single institution were evaluated.
ERCC1 mRNA expression was determined by quantitative real-time RT-PCR in pre-treatment tumor tissues. The
association of ERCC1 status with clinicopathological characteristics (age, histological grade, tumor size, parametrial
invasion, lymph node metastasis and FIGO stage) and treatment response were analyzed.
Results: No significant association between ERCC1 mRNA expression and clinicopathological characteristics were
observed. Patients with low ERCC1 mRNA level had a significantly higher rate of complete response (86.21%) than
patients with high level of ERCC1 expression (19.36%; p < 0.001). In the logistic regression analysis, low ERCC1
mRNA level retained an independent role in predicting complete response to CCCRT (P < 0.001). An ERCC1
expression level of 0.0901 was determined as an optimal cutoff value to identify complete response patients to
CCCRT treatment. The sensitivity for detection of a complete response was 81.48% with a specificity of 96.97%
(area under the curve, 0.893; 95% confidence interval, 0.804–0.983).
Conclusions: This is the first analysis of the association between ERCC1 mRNA levels and treatment response in
patients with LACSCC. Low ERCC1 mRNA level appears to be a highly specific predictor of response to CCCRT in
LACSCC.
Keywords: Excision repair cross-complementation group 1 (ERCC1), Cervical squamous cell carcinoma,
Chemoradiotherapy, Response predictionBackground
The current standard treatment of locally advanced cer-
vical cancer is cisplatin-based concurrent chemora-
diotherapy (CCCRT), followed by brachytherapy [1].
However, individual patients may show quite different
patterns of response against CCCRT; some can be cured,
but others cannot, and the latter may therefore suffer* Correspondence: nxzh1961@hotmail.com
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reproduction in any medium, provided the orsevere side effects [2]. Identification of biomarkers which
predict response to CCCRT will allow patients to avoid
toxicity associated with the ineffective therapy.
One of the most promising biomarkers for response pre-
diction is the excision repair cross-complementation
group 1 (ERCC1). ERCC1, which is involved in nucleotide
excision repair and associated with resistance to cisplatin-
based chemotherapy or chemoradiotherapy in various
types of cancer [3-10]. Earlier in vitro studies have linked
cisplatin resistance to the expression of ERCC1 mRNA in
cell lines of cervical cancers [11]. In a murine xenograft
model, upregulated ERCC1 expression is associated withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics of the patients
with LACSCC according to the ERCC1 mRNA levels
Characteristic ERCC1 mRNA P
High level Low level
Age, y
≤50 14 13
>50 15 18 0.622
Histologic grade
Well and moderately differentiated 12 19
Poorly differentiated 17 12 0.123
Tumor size, cm
≤4 8 12




Bilateral 3 5 0.774
Clinical lymph node involvement
N0 18 26
N1 11 5 0.056
FIGO stage
II 14 22
III 15 9 0.073
Hemoglobin levels at diagnosis, g/dL
≤11.3 8 5
>11.3 21 26 0.282
Platelets at diagnosis, ×109/L
≤320 26 24
>320 3 7 0.204
Abbreviations: LACSCC locally advanced cervical squamous cell carcinomas,
ERCC1 excision repair cross-complementation group 1, FIGO International
Federation of Gynecology and Obstetrics.
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cells [12]. However, the association of ERCC1 and treat-
ment response in clinical setting, especially for cervical
squamous cell carcinoma, has not be well documented.
The purpose of present study was to evaluate whether the
ERCC1 mRNA expression levels could predict the treat-
ment response of patients with locally advanced cervical




Cervical squamous cell carcinoma tissues and correspond-
ing non-tumorous tissues were obtained with informed
consent from sixty consecutive LACSCC patients who
underwent biopsy before CCCRT at Ningxia Medical
University General Hospital, between June 2009 and June
2010, and frozen in liquid nitrogen until further analysis.
Patients had a median age of 53 years (range 36 to 80 years)
and no patient received previous radiotherapy or chemo-
therapy. Histologically, all primary tumors were squamous
cell carcinoma. Staging was performed according to Inter-
national Federation of Gynecology and Obstetrics (FIGO)
staging system classification. Clinicopathological charac-
teristics of these patients are listed in Table 1. This study
was approved by the ethics committee of our hospital.
Treatment and response
The pretreatment evaluation included a review of the
patient’s history, physical examination, performance status,
biopsy and gynecologic examination under general
anesthesia, chest X-ray, complete blood count, blood
chemistry, and abdominal-pelvic magnetic resonance im-
aging. Cystoscopy and sigmoidoscopy were performed
when indicated.
Radiotherapy included external beam radiotherapy up to
50 Gy and low-dose rate brachytherapy, six applications of
6 Gy. Chemotherapy consisted of weekly intravenous
cisplatin administration (40 mg/m2) for 5 cycles concomi-
tant with external pelvic radiation. Treatment response
was clinically assessed according to the RECIST criteria
[13]. We categorized patients into two response groups:
the sensitive group and the resistant group. The sensitive
group included those patients who achieved a complete
response (CR as indicated in the RECIST criteria) and
remained in remission throughout the follow-up period.
The resistant group included patients who had persistent
disease (PR, SD and PD as indicated in the RECIST criteria)
after treatment or developed a relapse after remission.
RNA Extraction, reverse transcription and quantitative
real time RT-PCR (QRT-PCR) assays
RNA was isolated using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocolfrom the cancerous and corresponding non-tumorous tis-
sues. Concentration of total RNA was estimated by a
SmarSpec Plus spectrophotometer (BIO-RAD, Hercules,
CA,USA) and stored at −80°C.
After treatment with DNAfree (Ambion, Austin, TX,
USA) to remove chromosomal DNA, complementary DNA
(cDNA) was synthesized using SuperScript III Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA) and stored
at −20°C until use.
The mRNA expression levels of ERCC1 and beta-actin
were measured by quantitative RT-PCR using IQ 5
Multicolor Real-Time PCR Detection Systerm (BIO-RAD,
Hercules, CA, USA). The cycling conditions were as fol-
lows: 10 min of an initial denaturation step at 95°C, fol-
lowed by 40 cycles of 30 sec at 95°C, 30 sec at 58°C and
30 sec at 72°C. The following primers were used: ERCC1,
Figure 1 The mean value of ERCC1 mRNA expression between
sensitive and resistant groups.
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CACAATGATGCTGTTGG [14]; and beta-actin, forward:
TGACGTGGACATCCGCAAAG; Reverse: CTGGAAGGT
GGACAGCGAGG.PCR products were scanned, and quan-
tification was performed by the Quantity One program
(Bio-Rad, Hercules, CA, USA). The expression of beta-
actin was used as an internal control. The ERCC1 expres-
sion level was normalized to the beta-actin mRNA level
using the 2-△△Ct method [15].
Statistical analysis
The median relative ERCC1 mRNA expression level stan-
dardized for beta-actin was selected as cut-off value of high
and low level ERCC1 expression. Associations between
dichotomized ERCC1 mRNA levels and clinicopathological
characteristics were assessed for statistical significance
using a chi-square test. Logistic regression models were
used to identify independent predictive factors for treat-
ment response. Cut-off values for discrimination of ERCC1
mRNA levels and treatment response were derived from re-
ceiver operating curve data (ROC; area under the curve
and the 95% confidence interval). All reported P values are
two-sided, and P less than 0.05 was considered statistically
significant. SPSS 13.0 (SPSS Inc., Chicago, IL) was used for
the statistical analysis.
Results
ERCC1 mRNA expression levels were successfully mea-
sured in sixty patients. The median measured value of
ERCC1 mRNA was 23.06 (range, 18.78–25.46). The median
relative ERCC1 mRNA expression level standardized for
beta-actin was 0.0347 (range, 0.0028–5.4264). Thirty-one
(51.67%) patients were classified as having high level. No
significant differences were found in the clinicopathological
characteristics between the patients with high ERCC1
mRNA level and those with low level (Table 1).
All patients received the external beam radiotherapy and
brachytherapy as indicated in the protocol. For myelosurp-
pression and infectious complications, only 34 (56.67%)
patients received 5 cycles cisplatin-based concurrent
chemotherapy. The treatment response was evaluated by
CT imaging after treatment completion. Of the 60 patients
who entered the study, 33 (55%) patients had complete re-
sponse. Patients with low ERCC1 mRNA level had a sig-
nificantly higher complete response rate (86.21%) than
patients with high expression levels (19.36%; p < 0.001)
(Figure 1). In the logistic regression analysis, only low
ERCC1 mRNA level retained an independent role in pre-
dicting complete response to CCCRT (Table 2).
ROC analysis was applied to determine an ERCC1
mRNA value that best segregates patients into complete re-
sponse or non-complete response. An ERCC1 expression
level of 0.0901 was determined as an optimal cutoff value
to identify complete response to CCCRT treatment. Thesensitivity for detection of a complete response was 81.48%
with a specificity of 96.97% (area under the curve, 0.893;
95% confidence interval, 0.804–0.983) (Figure 2).
Discussions
The addition of concurrent cisplatin-based chemotherapy
to standard radiotherapy could reduce the risk of recur-
rence and disease-related death rates from locally advanced
cervical cancer by as much as 50% [16,17]. However, those
without a response will have toxicity helplessly. It would be
useful to predict the response and to search for novel
approaches for non-responders [18].
ERCC1 plays an important role in recognizing and re-
moving cisplatin–induced DNA adducts and repairs inter-
strand cross-links in DNA and recombination processes
[19,20]. Several preclinical and clinical studies have investi-
gated the expression of ERCC1 mRNA and protein in mul-
tiple cancer types and have demonstrated a correlation
between the ERCC1 expression levels and the treatment re-
sponse to platinum-based therapy and/or survival outcome
[3-10]. These results suggest that ERCC1 expression may
assist in selecting patients most likely to benefit from plat-
inum agent-based chemotherapy or chemoradiotherapy.
There are three other studies evaluated the relationship
of ERCC1 status and the treatment response or survival of
the patients with cervical carcinoma who received radio-
therapy or chemoradiotherapy. Liang et al. assessed the
ERCC1 expression of 50 patients with cervical squamous
cell carcinomas who received cisplatin-based concur-
rent chemoradiotherapy by immunohistochemistry (IHC)
method. They found ERCC1-negative patients had a
significantly higher complete response rate than ERCC1-
positive patients (P = 0.015). The 5-year overall survival
(OS) rates for the ERCC1-positive and ERCC1-negative
groups were 50.0% and 85.3%, respectively. For OS, lack of
ERCC1 expression was an independent prognostic factor
Table 2 Results of logistic regression analysis for clinical factors and response to CCCRT
B SE Wald P value OR 95% CI for OR
Age −0.104 0.064 2.599 0.107 0.902 0.795-1.023
Histologic grade −0.450 1.090 0.171 0.680 0.638 0.075-5.399
Tumor size 2.908 1.567 3.445 0.063 18.315 0.850-394.766
Parametrial invasion 2.773 1.878 2.180 0.140 16.011 0.403-635.705
Lymph node status −0.274 1.060 0.067 0.796 0.760 0.095-6.074
FIGO stage 2.471 1.797 1.891 0.169 11.836 0.349-400.843
Hemoglobin levels at diagnosis −0.326 1.252 0.068 0.795 0.722 0.062-8.398
Platelets at diagnosis −0.166 1.309 0.016 0.899 0.847 0.065-11.013
ERCC1 mRNA status 5.003 1.408 12.624 0.000 148.869 9.424-2351.736
Chemotherapy cycles −0.932 1.073 0.755 0.385 0.394 0.048-3.225
Abbreviations: CCCRT cisplatin-based concurrent chemoradiotherapy, B regression coefficient, SE standard error, Wald Wald value, OR odds ratio, CI confidence
interval, FIGO International Federation of Gynecology and Obstetrics, ERCC1 excision repair cross-complementation group 1.
Figure 2 ROC curve depicting sensitivity and specificity of
ERCC1 mRNA levels in predicting complete response of CCCRT.
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sion, using both mRNA and protein expression analysis,
with clinical outcome in cervical cancer patients treated
with radical radiotherapy. ERCC1 mRNA level was deter-
mined by real-time PCR, and ERCC1 protein expression
(FL297, 8F1) was measured using quantitative IHC.
ERCC1 protein expression levels using both FL297 and
8F1 antibodies were determined for 112 patients; mRNA
analysis was performed in 32 patients. In the 112 patients,
99 patients were squamous cell carcinomas, and 33
patients were adenocarcinomas. Low ERCC1 mRNA ex-
pression status was associated with worse OS (p = 0.046).
ERCC1 protein expression using the FL297 antibody, but
not the 8F1 antibody, was significantly associated with
both OS (p = 0.002) [22]. Hasegawa et al. analyzed the
ERCC1 expression of 36 patients with cervical adenocar-
cinoma by IHC method. Among the 25 patients who
received cisplatin-based chemotherapy or chemora-
diotherapy with cisplatin, those with high ERCC1 expres-
sion experienced significantly worse disease-free survival
than those with low ERCC1 expression (P = 0.002). More-
over, univariate and multivariate analyses revealed that
high ERCC1 expression was an independent prognostic
factor in patients receiving cisplatin-based chemotherapy
or chemoradiotherapy with cisplatin [23]. Our study is the
first analysis of the association between ERCC1 mRNA ex-
pression and treatment response in patients with cervical
squamous cell carcinomas who received radical cisplatin-
based concurrent chemoradiotherapy. Sixty patients were
evaluated in this study, which is the largest number among
these studies. We firstly found that cervical squamous cell
carcinomas patients with low ERCC1 mRNA level had a
significantly higher rate of complete response than patients
with high level of ERCC1 expression (P < 0.001). In the lo-
gistic regression analysis, low ERCC1 mRNA level retained
an independent role in predicting complete response to
CCCRT (P < 0.001).Although the results of our study are similar to Liang’s
and Hasegawa’s study, which are opposite to Doll’s study.
The first reason of these differences is the histology type
of enrolled patients was different. Squamous cell carcin-
oma comprises around 85% to 90% of uterine cervical can-
cer [24,25]. It has different biology behavior and treatment
response when compared with adenocacinoma [2,26]. In
Doll’s study, there are 11% patients with cervical adenocar-
cinoma. The second reason is that the treatment method
was different between two studies. In Doll’s study, they
used radiation alone. In fact, ERCC1 expression and the
response of chemotherapy also have interaction [10].
There are some shortages in this study. Firstly, we did
not perform IHC. High ERCC1 mRNA only signifies
ERCC1 DNA transcription and does not necessarily reflect
Bai et al. Radiation Oncology 2012, 7:221 Page 5 of 6
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be assessed by IHC. We will evaluate the ERCC1 protein
expression and the treatment response of LACSCC in fur-
ther study. Secondly, the number of patients was small.
We need do further research to validate the results in
large number patients. Lastly, due to the short follow-up
time, the association of ERCC1 mRNA levels and survival
was not performed in present study at this point.
Conclusions
This is the first study to evaluate the relationship of
ERCC1 mRNA levels and complete response of LACSCC
who underwent CCCRT. We have shown that ERCC1 ex-
pression patterns in pretreatment cancerous specimens
can be effectively used to predict response to CCCRT.
These results suggest that ERCC1 expression may assist in
selecting patients most likely to benefit from CCCRT. Fur-
ther investigation is required to determine whether these
assays are sufficiently reliable to use routinely as a basis to
select specific patient treatments.
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